{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T09:58:34Z","timestamp":1793267914052,"version":"4.5.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.critrevonc.2013.02.008","type":"journal-article","created":{"date-parts":[[2013,3,21]],"date-time":"2013-03-21T15:48:51Z","timestamp":1363880931000},"page":"19-29","source":"Crossref","is-referenced-by-count":27,"title":["Biomolecular markers of cancer-associated thromboembolism"],"prefix":"10.1016","volume":"88","author":[{"given":"Diana L.","family":"Hanna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard H.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted","family":"Wun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2013.02.008_bib0005","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1001\/archinte.166.4.458","article-title":"Incidence of venous thromboembolism and its effect on survival among patients with common cancers","volume":"166","author":"Chew","year":"2006","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0010","series-title":"The risk of venous thromboembolism in patients with cancer","author":"Khorana","year":"2008"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0015","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1200\/JCO.2006.07.4393","article-title":"Incidence of venous thromboembolism and the impact on survival in breast cancer patients","volume":"25","author":"Chew","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0020","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2005.04.2150","article-title":"Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival","volume":"24","author":"Alcalay","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0025","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJM200012213432504","article-title":"Prognosis of cancers associated with venous thromboembolism","volume":"343","author":"Sorensen","year":"2000","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0030","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1470-2045(05)70207-2","article-title":"Cancer and venous thromboembolism","volume":"6","author":"Prandoni","year":"2005","journal-title":"Lancet Oncology"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0035","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0040","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1182\/asheducation-2004.1.439","article-title":"Deep venous thrombosis","author":"Lopez","year":"2004","journal-title":"Hematology American Society of Hematology: Education Program"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0045","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.beha.2008.12.001","article-title":"Epidemiology of cancer-related venous thromboembolism","volume":"22","author":"Wun","year":"2009","journal-title":"Best Practice and Research. Clinical Haematology"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0050","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.293.6.715","article-title":"Malignancies, prothrombotic mutations, and the risk of venous thrombosis","volume":"293","author":"Blom","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0055","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"Prandoni","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0060","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1002\/cncr.23062","article-title":"Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients","volume":"110","author":"Khorana","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0065","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1002\/cncr.21496","article-title":"Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study","volume":"104","author":"Khorana","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0070","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.1182\/blood-2010-02-270116","article-title":"Prediction of venous thromboembolism in cancer patients","volume":"116","author":"Ay","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0075","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1001\/archinte.164.2.190","article-title":"Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon","volume":"164","author":"Otten","year":"2004","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0080","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1055\/s-2007-994915","article-title":"The thrombophilic state induced by therapeutic agents in the cancer patient","volume":"25","author":"Lee","year":"1999","journal-title":"Seminars in Thrombosis and Hemostasis"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0085","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.thromres.2005.10.015","article-title":"Chemotherapy-induced thrombosis","volume":"118","author":"Haddad","year":"2006","journal-title":"Thrombosis Research"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0090","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jama.299.8.914","article-title":"Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia","volume":"299","author":"Bennett","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0095","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1002\/cncr.11700","article-title":"Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin","volume":"98","author":"Wun","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0100","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/djj189","article-title":"Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients","volume":"98","author":"Bohlius","year":"2006","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0105","first-page":"89","article-title":"Venous thromboembolism and survival in patients with high-grade glioma","volume":"9","author":"Simanek","year":"2007","journal-title":"Neurooncology"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0110","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1538-7836.2006.01804.x","article-title":"Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study","volume":"4","author":"Blom","year":"2006","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0115","unstructured":"Virchow RLK. Thrombose und Embolie. Gef\u00e4ssentz\u00fcndung und septische Infektion [Gesammelte Abhandlungen zur wissenschaftlichen Medicin]. Frankfurt am Main: Von Meidinger & Son; 1856, p. 219\u2013732 [English translation by Matzdorff AC, Bell WR, in Thrombosis and Emboli. Canton, MA: Science History Publications, 1998; in German]."},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0120","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1172\/JCI110203","article-title":"A factor X-activating cysteine protease from malignant tissue","volume":"67","author":"Gordon","year":"1981","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0125","first-page":"403","article-title":"From Trousseau to angiogenesis: the link between the haemostatic system and cancer","volume":"64","author":"Nijziel","year":"2006","journal-title":"Netherlands Journal of Medicine"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0130","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/sj.neo.7900263","article-title":"The hypercoagulable state of malignancy: pathogenesis and current debate","volume":"4","author":"Caine","year":"2002","journal-title":"Neoplasia"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0135","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1096\/fj.02-0574fje","article-title":"Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets","volume":"17","author":"Muller","year":"2003","journal-title":"FASEB Journal"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0140","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/nm841","article-title":"Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein","volume":"9","author":"Bogdanov","year":"2003","journal-title":"Nature Medicine"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0145","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.thromres.2008.09.005","article-title":"Circulating procoagulant microparticles in patients with venous thromboembolism","volume":"123","author":"Ay","year":"2009","journal-title":"Thrombosis Research"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0150","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.thromres.2007.12.023","article-title":"Tissue factor activity is increased in a combined platelet and microparticle sample from cancer patients","volume":"122","author":"Tilley","year":"2008","journal-title":"Thrombosis Research"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0155","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1200\/JCO.2009.22.6324","article-title":"Role of tissue factor in cancer","volume":"27","author":"Kasthuri","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0160","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1182\/blood.V82.2.513.513","article-title":"C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor","volume":"82","author":"Cermak","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0165","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.cardiores.2005.05.010","article-title":"C-reactive protein induces tissue factor expression and promotes smooth muscle and endothelial cell proliferation","volume":"68","author":"Cirillo","year":"2005","journal-title":"Cardiovascular Research"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0170","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.atherosclerosis.2008.05.060","article-title":"C-reactive protein stimulates superoxide anion release and tissue factor activity in vivo","volume":"203","author":"Devaraj","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0175","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1084\/jem.20021868","article-title":"Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin","volume":"197","author":"Falati","year":"2003","journal-title":"Journal of Experimental Medicine"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0180","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1084\/jem.191.8.1413","article-title":"P-Selectin glycoprotein ligand 1 (PSGL-1) is expressed on platelets and can mediate platelet-endothelial interactions in vivo","volume":"191","author":"Frenette","year":"2000","journal-title":"Journal of Experimental Medicine"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0185","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1161\/ATVBAHA.108.182188","article-title":"Biomarkers and venous thromboembolism","volume":"29","author":"Pabinger","year":"2009","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0190","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1538-7836.2010.04069.x","article-title":"Thrombosis risk and survival in cancer patients with elevated C-reactive protein","volume":"9","author":"Kanz","year":"2011","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0195","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1161\/ATVBAHA.108.174359","article-title":"C-reactive protein isoforms differ in their effects on thrombus growth","volume":"28","author":"Molins","year":"2008","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0200","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1538-7836.2010.04131.x","article-title":"The platelet contribution to cancer progression","volume":"9","author":"Bambace","year":"2011","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0205","doi-asserted-by":"crossref","first-page":"V215","DOI":"10.1016\/S0049-3848(01)00285-7","article-title":"Molecular basis for the relationship between thrombosis and cancer","volume":"102","author":"Rickles","year":"2001","journal-title":"Thrombosis Research"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0210","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10753-009-9116-4","article-title":"Serum C-reactive protein (CRP) levels in cancer patients are linked with tumor burden and are reduced by anti-hypertensive medication","volume":"32","author":"Koukourakis","year":"2009","journal-title":"Inflammation"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0215","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1160\/TH04-11-0745","article-title":"Basal high-sensitivity-C-reactive protein levels in patients with spontaneous venous thromboembolism","volume":"93","author":"Vormittag","year":"2005","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0220","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/annonc\/mdj068","article-title":"Risk factors for venous thromboembolic events in cancer patients","volume":"17","author":"Kroger","year":"2006","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0225","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.21.7752","article-title":"D-dimer and prothrombin fragment 1+2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study","volume":"27","author":"Ay","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00001721-200201000-00001","article-title":"Advanced prostate cancer activates coagulation: a controlled study of activation markers of coagulation in ambulatory patients with localized and advanced prostate cancer","volume":"13","author":"Kohli","year":"2002","journal-title":"Blood Coagulation and Fibrinolysis"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0235","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1006\/gyno.1993.1142","article-title":"Prothrombin fragment F 1+2 plasma concentrations in patients with gynecologic malignancies","volume":"49","author":"Hanzal","year":"1993","journal-title":"Gynecologic Oncology"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0240","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/00001721-199304000-00006","article-title":"Activation of coagulation and fibrinolysis in patients with lung cancer: relation to tumour stage and prognosis","volume":"4","author":"Seitz","year":"1993","journal-title":"Blood Coagulation and Fibrinolysis"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0245","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/jcp.2010.076349","article-title":"Elevated D-dimers are also a marker of underlying malignancy and increased mortality in the absence of venous thromboembolism","volume":"63","author":"Knowlson","year":"2010","journal-title":"Journal of Clinical Pathology"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0250","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/1076029607309176","article-title":"Elevated levels of prothrombin fragment 1+2 indicate high risk of thrombosis","volume":"14","author":"Ota","year":"2008","journal-title":"Clinical and Applied Thrombosis and Hemostasis"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0255","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1055\/s-0038-1656062","article-title":"Prothrombin fragment F1+2 is not predictive for recurrent venous thromboembolism","volume":"77","author":"Kyrle","year":"1997","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0260","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/00001721-200404000-00004","article-title":"Clotting activation after oral anticoagulant therapy discontinuation: a risk factor for recurrent venous thromboembolism","volume":"15","author":"Poli","year":"2004","journal-title":"Blood Coagulation and Fibrinolysis"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0265","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1200\/JCO.2010.32.8294","article-title":"Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study","volume":"29","author":"Ay","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0270","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1182\/blood-2008-02-142422","article-title":"High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS)","volume":"112","author":"Ay","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0275","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00005-006-0010-6","article-title":"P-selectin mediates adhesion of leukocytes, platelets, and cancer cells in inflammation, thrombosis, and cancer growth and metastasis","volume":"54","author":"Chen","year":"2006","journal-title":"Archivum Immunologiae et Therapiae Experimentalis"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0280","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.2174\/0929867043364720","article-title":"P-selectin cell adhesion molecule in inflammation, thrombosis, cancer growth and metastasis","volume":"11","author":"Geng","year":"2004","journal-title":"Current Medicinal Chemistry"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0285","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1084\/jem.20082297","article-title":"Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo","volume":"206","author":"Thomas","year":"2009","journal-title":"Journal of Experimental Medicine"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0290","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1161\/ATVBAHA.109.190827","article-title":"High factor VIII levels independently predict venous thromboembolism in cancer patients: the cancer and thrombosis study","volume":"29","author":"Vormittag","year":"2009","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0295","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.ejim.2007.06.036","article-title":"Relation between hemostatic parameters and prognostic\/predictive factors in breast cancer","volume":"19","author":"Yigit","year":"2008","journal-title":"European Journal of Internal Medicine"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0300","doi-asserted-by":"crossref","first-page":"36","DOI":"10.5301\/JBM.2008.4255","article-title":"Coagulation factor levels in non-metastatic colorectal cancer patients","volume":"23","author":"Battistelli","year":"2008","journal-title":"International Journal of Biological Markers"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0305","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1538-7836.2003.00083.x","article-title":"Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment","volume":"1","author":"Minnema","year":"2003","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0310","doi-asserted-by":"crossref","first-page":"206","DOI":"10.5301\/JBM.2008.4592","article-title":"The effect of venous thromboembolism on survival of cancer patients and its relationship with serum levels of factor VIII and vascular endothelial growth factor: a prospective matched-paired study","volume":"21","author":"Dogan","year":"2006","journal-title":"International Journal of Biological Markers"},{"issue":"Suppl. 2","key":"10.1016\/j.critrevonc.2013.02.008_bib0315","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/S0049-3848(10)70022-0","article-title":"Predictive value of tissue factor bearing microparticles in cancer associated thrombosis","volume":"125","author":"Zwicker","year":"2010","journal-title":"Thrombosis Research"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0320","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1158\/1078-0432.CCR-06-2351","article-title":"Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer","volume":"13","author":"Khorana","year":"2007","journal-title":"Clinical Cancer Research"},{"issue":"Suppl. 1","key":"10.1016\/j.critrevonc.2013.02.008_bib0325","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1002\/ajh.23143","article-title":"Cancer and coagulation","volume":"87","author":"Khorana","year":"2012","journal-title":"American Journal of Hematology"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0330","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1538-7836.2007.02369.x","article-title":"Microparticle-associated tissue factor activity: a link between cancer and thrombosis","volume":"5","author":"Tesselaar","year":"2007","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0335","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1160\/TH06-03-0141","article-title":"Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer","volume":"97","author":"Hron","year":"2007","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0340","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1111\/j.1538-7836.2008.03156.x","article-title":"Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer","volume":"6","author":"Khorana","year":"2008","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0345","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.thromres.2009.09.019","article-title":"Increased microparticle tissue factor activity in cancer patients with Venous thromboembolism","volume":"125","author":"Manly","year":"2010","journal-title":"Thrombosis Research"},{"issue":"Suppl. 2","key":"10.1016\/j.critrevonc.2013.02.008_bib0350","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S0049-3848(07)70128-7","article-title":"Targeting patients for anticoagulant prophylaxis trials in patients with cancer: who is at highest risk?","volume":"120","author":"White","year":"2007","journal-title":"Thrombosis Research"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0355","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/j.1538-7836.2012.04754.x","article-title":"Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients","volume":"10","author":"Thaler","year":"2012","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0360","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1111\/j.1538-7836.2009.03504.x","article-title":"Microparticle-associated tissue factor activity in cancer patients with and without thrombosis","volume":"7","author":"Tesselaar","year":"2009","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0365","doi-asserted-by":"crossref","first-page":"6830","DOI":"10.1158\/1078-0432.CCR-09-0371","article-title":"Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy","volume":"15","author":"Zwicker","year":"2009","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0370","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00277-010-1111-1","article-title":"Circulating procoagulant microparticles in cancer patients","volume":"90","author":"Thaler","year":"2011","journal-title":"Annals of Hematology"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0375","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.1158\/0008-5472.CAN-04-3156","article-title":"In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy","volume":"65","author":"Ma","year":"2005","journal-title":"Cancer Research"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0380","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1538-7836.2009.03300.x","article-title":"Chemotherapeutic agents doxorubicin and epirubicin induce a procoagulant phenotype on endothelial cells and blood monocytes","volume":"7","author":"Swystun","year":"2009","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0385","doi-asserted-by":"crossref","first-page":"127","DOI":"10.5482\/ha-1164","article-title":"Clinical significance of circulating microparticles for venous thromboembolism in cancer patients","volume":"32","author":"Thaler","year":"2012","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0390","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1111\/j.1538-7836.2004.00991.x","article-title":"Risk factors for venous thrombosis in medical inpatients: validation of a thrombosis risk score","volume":"2","author":"Zakai","year":"2004","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0395","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1538-7836.2009.03498.x","article-title":"Mean platelet volume is a risk factor for venous thromboembolism: the Tromso Study, Tromso, Norway","volume":"8","author":"Braekkan","year":"2010","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0400","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1001\/archinte.162.10.1182","article-title":"Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology","volume":"162","author":"Tsai","year":"2002","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0405","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1538-7836.2009.03680.x","article-title":"High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS)","volume":"8","author":"Simanek","year":"2010","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0410","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0415","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.thromres.2010.05.012","article-title":"Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy","volume":"126","author":"Connolly","year":"2010","journal-title":"Thrombosis Research"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0420","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1002\/1097-0142(20011101)92:9<2399::AID-CNCR1588>3.0.CO;2-W","article-title":"Tumor-related leukocytosis is linked with poor prognosis in patients with lung carcinoma","volume":"92","author":"Kasuga","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0425","doi-asserted-by":"crossref","first-page":"6240","DOI":"10.1200\/JCO.2005.06.866","article-title":"Prognostic factors in advanced cancer patients: evidence-based clinical recommendations\u2014a study by the Steering Committee of the European Association for Palliative Care","volume":"23","author":"Maltoni","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0430","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1023\/A:1012527006566","article-title":"Alterations of routine blood tests in adult patients with soft tissue sarcomas: relationships to cytokine serum levels and prognostic significance","volume":"12","author":"Ruka","year":"2001","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0435","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1200\/JCO.2006.09.0274","article-title":"Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial","volume":"25","author":"Schmidt","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0440","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1160\/TH08-05-0339","article-title":"Elevated white blood cell count and outcome in cancer patients with venous thromboembolism. Findings from the RIETE Registry","volume":"100","author":"Trujillo-Santos","year":"2008","journal-title":"Thrombosis and Haemostasis"},{"issue":"Suppl. 1","key":"10.1016\/j.critrevonc.2013.02.008_bib0445","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/S0049-3848(12)70009-9","article-title":"Risk assessment for cancer-associated thrombosis: what is the best approach?","volume":"129","author":"Khorana","year":"2012","journal-title":"Thrombosis Research"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0450","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/annonc\/mdr524","article-title":"Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the \u2018SENDO experience\u2019","volume":"23","author":"Mandala","year":"2012","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0455","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1200\/JCO.2011.35.5669","article-title":"High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis","volume":"29","author":"Moore","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0460","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11739-012-0784-y","article-title":"A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score","volume":"7","author":"Verso","year":"2012","journal-title":"Internal and Emergency Medicine"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0465","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.206.206","article-title":"Venous thromboembolism (VTE) prevention with semuloparin in cancer patients initiating chemotherapy: benefit\u2013risk assessment by VTE risk in SAVE-ONCO [abstract 206]","volume":"118","author":"George","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0470","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1108898","article-title":"Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer","volume":"366","author":"Agnelli","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0475","series-title":"Biennial Multidisciplinary Congress of the European CanCer Organisation and European Society for Medical Oncology","article-title":"Venous thromboembolism (VTE) in cancer patients receiving chemotherapy: a real-world analysis of VTE risk and the impact of VTE on healthcare expenditure","author":"Lyman","year":"2011"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0480","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.ctrv.2009.08.009","article-title":"Anticoagulation therapy for prevention and treatment of venous thromboembolic events in cancer patients: a review of current guidelines","volume":"35","author":"Petersen","year":"2009","journal-title":"Cancer Treatment Reviews"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0485","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.1200\/JCO.2007.14.1283","article-title":"American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer","volume":"25","author":"Lyman","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0490","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.1378\/chest.1412S3","article-title":"Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Guyatt","year":"2012","journal-title":"Chest"},{"issue":"Suppl. 2","key":"10.1016\/j.critrevonc.2013.02.008_bib0495","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1016\/S0049-3848(10)70029-3","article-title":"Prevention and treatment of venous thromboembolism among patients with cancer: the American Society of Clinical Oncology Guidelines","volume":"125","author":"Lyman","year":"2010","journal-title":"Thrombosis Research"},{"key":"10.1016\/j.critrevonc.2013.02.008_bib0500","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1056\/NEJMe1113672","article-title":"Routine heparin for patients with cancer? One answer, more questions","volume":"366","author":"Akl","year":"2012","journal-title":"New England Journal of Medicine"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842813000516?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842813000516?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T04:58:36Z","timestamp":1595566716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842813000516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S1040842813000516"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2013.02.008","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}